Background
Most (>50%) new HIV diagnoses occur in adolescents and young adults (AYA; 14-35 yrs). Onset of severe mental illnesses (SMI) like schizophrenia and bipolar disorder (BD) coincides with this developmental period and significantly elevates HIV risk. Very little research has examined use of highly-effective pre-exposure prophylaxis (PrEP) for HIV prevention among AYA-SMI.
Methods
We utilized the MarketScan® Claims Database from 2012-2023 to identify commercially insured AYA ages 14-35 with SMI defined as two outpatient claims (different dates) or a single inpatient claim for an SMI diagnosis. Restrictions were applied to account for presumed HIV post-exposure prophylaxis and HepB treatment. Patients were followed in the database for the duration of available data following the index date, which was the date of initial diagnosis. Covariates describing STI encounters and substance use disorders were included. The outcomes were: 1) New HIV diagnosis, 2) prescription of ≥3-months of PrEP. We subsequently performed descriptive statistics to characterize PrEP use.
Results
The cohort included 181,587 AYA (157,353 with BD and 24,234 with schizophrenia). Mean age was 23.9 years. There were 227 new HIV diagnoses, 187 among AYA with BD and 40 with schizophrenia. There was no difference in odds of acquiring HIV (aOR=0.80, p=.23) by diagnosis. There were 782 AYA prescribed PrEP (706 with BD, 76 with SCZ). AYA with schizophrenia were less likely to receive PrEP (aOR=0.47, p<.001). Males were more likely to acquire HIV (aOR=6.13, p<.001) and be prescribed PrEP (aOR=24.0, p<.001). Comorbid stimulant use disorder was associated with HIV (aOR=1.80, p=.007), and PrEP (aOR=1.60, p =.001). Cannabis (aOR=0.77, p=.001) and opioid (aOR=0.66, p<.001) use disorders were associated with lower odds of PrEP prescription.
Mean duration of PrEP coverage was 278 days (Median=120) among AYA with BD and 182 (Median=90) among AYA with SCZ. In 2022-2023, 6 AYA were prescribed cabotegravir for PrEP (all with BD) and only one had previously utilized another LAI agent. Among AYA receiving CAB, a median of 4 injections (max: 8) were received. There were 35 (26 with BD, 9 with SCZ) who acquired HIV with prior PrEP prescription.
Conclusions
PrEP use among commercially-insured AYA with SMI was relatively low including among AYA with multiple encounters for STIs, despite this being a CDC eligibility criteria. Very low use of LAI PrEP was identified. Targeted and concerted efforts are needed to expand PrEP use among AYA-SMI.
Table or Figure
